Using pharmacogenetic analysis in clinical management with clozapine

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2023-10-01 DOI:10.1002/pnp.808

Nilema Nasrine, Chloe Stevens, Hoi‐Ying Tam, Vimal Sivasanker

引用次数: 0

Abstract

A limited response to clozapine treatment is a familiar clinical scenario in patients with treatment‐resistant schizophrenia. Here, the authors present a case where pharmacogenetic analysis was able to guide clinical management, and the discussion is expanded into the role of clinic genomics in personalised medicine.

查看原文本刊更多论文

药物遗传学分析在氯氮平临床治疗中的应用

对氯氮平治疗的有限反应是难治性精神分裂症患者常见的临床情况。在这里，作者提出了一个药物遗传分析能够指导临床管理的案例，并且讨论扩展到临床基因组学在个性化医疗中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.